Development and screening of contrast agents for in vivo imaging of Parkinson's disease

Krista L. Neal, Naomi B. Shakerdge, Steven S. Hou, William E. Klunk, Chester A. Mathis, Evgueni E. Nesterov, Timothy M. Swager, Pamela J McLean, Brian J. Bacskai

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Purpose: The goal was to identify molecular imaging probes that would enter the brain, selectively bind to Parkinson's disease (PD) pathology, and be detectable with one or more imaging modalities. Procedure: A library of organic compounds was screened for the ability to bind hallmark pathology in human Parkinson's and Alzheimer's disease tissue, alpha-synuclein oligomers and inclusions in two cell culture models, and alpha-synuclein aggregates in cortical neurons of a transgenic mouse model. Finally, compounds were tested for blood-brain barrier permeability using intravital microscopy. Results: Several lead compounds were identified that bound the human PD pathology, and some showed selectivity over Alzheimer's pathology. The cell culture models and transgenic mouse models that exhibit alpha-synuclein aggregation did not prove predictive for ligand binding. The compounds had favorable physicochemical properties, and several were brain permeable. Conclusions: Future experiments will focus on more extensive evaluation of the lead compounds as PET ligands for clinical imaging of PD pathology.

Original languageEnglish (US)
Pages (from-to)585-595
Number of pages11
JournalMolecular Imaging and Biology
Volume15
Issue number5
DOIs
StatePublished - Oct 2013

Fingerprint

Contrast Media
Parkinson Disease
alpha-Synuclein
Pathology
Transgenic Mice
Cell Culture Techniques
Ligands
Molecular Probes
Molecular Imaging
Aptitude
Brain
Blood-Brain Barrier
Permeability
Alzheimer Disease
Neurons

Keywords

  • Alpha-Synuclein
  • Blood-brain barrier
  • Dementia with Lewy bodies
  • In vivo imaging
  • Lewy bodies
  • Lewy Neurites
  • Molecular imaging
  • Parkinson's disease
  • PET

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Neal, K. L., Shakerdge, N. B., Hou, S. S., Klunk, W. E., Mathis, C. A., Nesterov, E. E., ... Bacskai, B. J. (2013). Development and screening of contrast agents for in vivo imaging of Parkinson's disease. Molecular Imaging and Biology, 15(5), 585-595. https://doi.org/10.1007/s11307-013-0634-y

Development and screening of contrast agents for in vivo imaging of Parkinson's disease. / Neal, Krista L.; Shakerdge, Naomi B.; Hou, Steven S.; Klunk, William E.; Mathis, Chester A.; Nesterov, Evgueni E.; Swager, Timothy M.; McLean, Pamela J; Bacskai, Brian J.

In: Molecular Imaging and Biology, Vol. 15, No. 5, 10.2013, p. 585-595.

Research output: Contribution to journalArticle

Neal, KL, Shakerdge, NB, Hou, SS, Klunk, WE, Mathis, CA, Nesterov, EE, Swager, TM, McLean, PJ & Bacskai, BJ 2013, 'Development and screening of contrast agents for in vivo imaging of Parkinson's disease', Molecular Imaging and Biology, vol. 15, no. 5, pp. 585-595. https://doi.org/10.1007/s11307-013-0634-y
Neal, Krista L. ; Shakerdge, Naomi B. ; Hou, Steven S. ; Klunk, William E. ; Mathis, Chester A. ; Nesterov, Evgueni E. ; Swager, Timothy M. ; McLean, Pamela J ; Bacskai, Brian J. / Development and screening of contrast agents for in vivo imaging of Parkinson's disease. In: Molecular Imaging and Biology. 2013 ; Vol. 15, No. 5. pp. 585-595.
@article{71a505cbd2ca4bf49656e7703831f81d,
title = "Development and screening of contrast agents for in vivo imaging of Parkinson's disease",
abstract = "Purpose: The goal was to identify molecular imaging probes that would enter the brain, selectively bind to Parkinson's disease (PD) pathology, and be detectable with one or more imaging modalities. Procedure: A library of organic compounds was screened for the ability to bind hallmark pathology in human Parkinson's and Alzheimer's disease tissue, alpha-synuclein oligomers and inclusions in two cell culture models, and alpha-synuclein aggregates in cortical neurons of a transgenic mouse model. Finally, compounds were tested for blood-brain barrier permeability using intravital microscopy. Results: Several lead compounds were identified that bound the human PD pathology, and some showed selectivity over Alzheimer's pathology. The cell culture models and transgenic mouse models that exhibit alpha-synuclein aggregation did not prove predictive for ligand binding. The compounds had favorable physicochemical properties, and several were brain permeable. Conclusions: Future experiments will focus on more extensive evaluation of the lead compounds as PET ligands for clinical imaging of PD pathology.",
keywords = "Alpha-Synuclein, Blood-brain barrier, Dementia with Lewy bodies, In vivo imaging, Lewy bodies, Lewy Neurites, Molecular imaging, Parkinson's disease, PET",
author = "Neal, {Krista L.} and Shakerdge, {Naomi B.} and Hou, {Steven S.} and Klunk, {William E.} and Mathis, {Chester A.} and Nesterov, {Evgueni E.} and Swager, {Timothy M.} and McLean, {Pamela J} and Bacskai, {Brian J.}",
year = "2013",
month = "10",
doi = "10.1007/s11307-013-0634-y",
language = "English (US)",
volume = "15",
pages = "585--595",
journal = "Molecular Imaging and Biology",
issn = "1536-1632",
publisher = "Springer New York",
number = "5",

}

TY - JOUR

T1 - Development and screening of contrast agents for in vivo imaging of Parkinson's disease

AU - Neal, Krista L.

AU - Shakerdge, Naomi B.

AU - Hou, Steven S.

AU - Klunk, William E.

AU - Mathis, Chester A.

AU - Nesterov, Evgueni E.

AU - Swager, Timothy M.

AU - McLean, Pamela J

AU - Bacskai, Brian J.

PY - 2013/10

Y1 - 2013/10

N2 - Purpose: The goal was to identify molecular imaging probes that would enter the brain, selectively bind to Parkinson's disease (PD) pathology, and be detectable with one or more imaging modalities. Procedure: A library of organic compounds was screened for the ability to bind hallmark pathology in human Parkinson's and Alzheimer's disease tissue, alpha-synuclein oligomers and inclusions in two cell culture models, and alpha-synuclein aggregates in cortical neurons of a transgenic mouse model. Finally, compounds were tested for blood-brain barrier permeability using intravital microscopy. Results: Several lead compounds were identified that bound the human PD pathology, and some showed selectivity over Alzheimer's pathology. The cell culture models and transgenic mouse models that exhibit alpha-synuclein aggregation did not prove predictive for ligand binding. The compounds had favorable physicochemical properties, and several were brain permeable. Conclusions: Future experiments will focus on more extensive evaluation of the lead compounds as PET ligands for clinical imaging of PD pathology.

AB - Purpose: The goal was to identify molecular imaging probes that would enter the brain, selectively bind to Parkinson's disease (PD) pathology, and be detectable with one or more imaging modalities. Procedure: A library of organic compounds was screened for the ability to bind hallmark pathology in human Parkinson's and Alzheimer's disease tissue, alpha-synuclein oligomers and inclusions in two cell culture models, and alpha-synuclein aggregates in cortical neurons of a transgenic mouse model. Finally, compounds were tested for blood-brain barrier permeability using intravital microscopy. Results: Several lead compounds were identified that bound the human PD pathology, and some showed selectivity over Alzheimer's pathology. The cell culture models and transgenic mouse models that exhibit alpha-synuclein aggregation did not prove predictive for ligand binding. The compounds had favorable physicochemical properties, and several were brain permeable. Conclusions: Future experiments will focus on more extensive evaluation of the lead compounds as PET ligands for clinical imaging of PD pathology.

KW - Alpha-Synuclein

KW - Blood-brain barrier

KW - Dementia with Lewy bodies

KW - In vivo imaging

KW - Lewy bodies

KW - Lewy Neurites

KW - Molecular imaging

KW - Parkinson's disease

KW - PET

UR - http://www.scopus.com/inward/record.url?scp=84885313978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885313978&partnerID=8YFLogxK

U2 - 10.1007/s11307-013-0634-y

DO - 10.1007/s11307-013-0634-y

M3 - Article

C2 - 23624948

AN - SCOPUS:84885313978

VL - 15

SP - 585

EP - 595

JO - Molecular Imaging and Biology

JF - Molecular Imaging and Biology

SN - 1536-1632

IS - 5

ER -